8-K: Turnstone Biologics to be Acquired by XOMA Royalty in Cash and CVR Deal Amidst Operational Wind-Down

Turnstone Biologics Corp. has entered into a definitive merger agreement to be acquired by XOMA Royalty Corporation for $0.34 per share in cash plus one contingent value right, with the transaction expected to close in August 2025.

Summary

• Turnstone Biologics Corp. (the Company) entered into an Agreement and Plan of Merger (the Merger Agreement) with XOMA Royalty Corporation (XOMA) and Merger Sub on June 26, 2025.
• XOMA will acquire all outstanding shares of Turnstone common stock through a cash tender offer for a price of $0.34 per share in cash (the Cash Amount) plus one non-transferable contingent value right (CVR).
• The CVR represents the right to receive potential cash payments up to an aggregate of $1,110,000 from tax receivables and a lease security deposit, plus 'Net Cash Excess,' minus 'Net Cash Shortfall,' contingent on receipt within one year of the merger closing.
• The Company's Board of Directors unanimously determined the transaction to be fair and in the best interest of stockholders, recommending they accept the offer.
• XOMA is required to commence the tender offer no later than 10 business days after June 26, 2025 (by July 10, 2025).
• The merger will be effected under Section 251(h) of the Delaware General Corporation Law (DGCL) following the tender offer, without additional stockholder approvals.
• Outstanding Company Stock Options will be cancelled and terminated for no consideration.
• Outstanding Company Restricted Stock Units will accelerate vesting and be cancelled in exchange for the Cash Amount ($0.34) and one CVR per unit.
• XOMA's obligation to accept tendered shares is subject to conditions, including a minimum tender of one share more than 50% of outstanding shares, absence of legal restraints, accuracy of representations, compliance with covenants, and a 'Closing Net Cash' of no less than $2,000,000.
• The transaction is not subject to a financing condition.
• A termination fee of $350,000 is payable by Turnstone to XOMA under certain circumstances, including if Turnstone enters into a superior proposal.
• An expense reimbursement fee up to $350,000 is payable by Turnstone to XOMA if the 'Closing Net Cash Condition' fails.
• Turnstone also entered into an Asset Purchase Agreement with H. Lee Moffitt Cancer Center and Research Institute, Inc. (Moffitt) on June 26, 2025, to sell assets related to its TIDAL-01 program.
• The asset sale to Moffitt is for approximately $3.0 million, with $1.8 million placed into an escrow account.
• Moffitt will assume Turnstone's $20,000,000 Contingent Milestone Payment Obligation under the Myst Merger Agreement, but disclaims any obligation to further develop the associated intellectual property.
• The Alliance Agreements with Moffitt are terminated, and mutual releases are granted, with Turnstone's accrued payment obligations of $2,967,238 (including a $1,597,527 termination fee, $727,920 in outstanding invoices, and $641,790 from contract 19VA007-AR2-S11) being satisfied by offset against the purchase price or escrow release.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative due to the very low acquisition price, the cancellation of stock options for no consideration, and the effective wind-down of the company's core operations and R&D activities. While there's a CVR, its contingent and non-transferable nature limits its immediate positive impact. The transaction represents a distressed sale rather than a growth-oriented acquisition.

Positives

• The Company's Board of Directors unanimously approved the acquisition, deeming it fair and in the best interest of stockholders, and recommended acceptance of the offer.
• The transaction provides a fixed cash component of $0.34 per share, offering immediate and certain value to stockholders.
• The Contingent Value Right (CVR) provides a potential for additional future payments from existing assets (tax receivables, lease security deposit, Net Cash Excess).
• The Asset Purchase Agreement with Moffitt results in the sale of the TIDAL-01 program assets for approximately $3.0 million, with $1.8 million placed in escrow, contributing to the company's cash position.
• Moffitt's assumption of the $20,000,000 Contingent Milestone Payment Obligation under the Myst Merger Agreement significantly reduces Turnstone's future liabilities related to that program.
• The transaction is not subject to a financing condition, reducing uncertainty regarding its completion.
• Support agreements from stockholders representing approximately 25.2% of Turnstone common stock indicate significant insider backing for the merger.

Negatives

• All outstanding Company Stock Options will be cancelled for no consideration, resulting in a complete loss of value for option holders.
• The Contingent Value Rights (CVRs) are non-transferable and not registered with the SEC, limiting liquidity and potential market value for recipients.
• CVR payments are contingent and will not be received if the CVR proceeds are received after one year following the merger closing, introducing a time-sensitive risk.
• The cash component of $0.34 per share is a very low valuation for a publicly traded biotechnology company, suggesting significant distress or limited future prospects.
• The company is undergoing a 'wind-down process' of its operations and research and development activities, indicating a cessation of its core business and likely significant job losses.
• Significant severance and other payments are being made to the Chief Executive Officer ($686,757 cash, $33,264.60 COBRA, up to $5,000 outplacement, plus $148,874.68 contingent on merger closing) and Chief Operating Officer ($354,327 cash, $8,218.49 COBRA, up to $5,000 outplacement, plus $64,035 contingent on merger closing).
• Turnstone is subject to a five-year non-compete clause regarding the TIL Program following the closing of the asset sale to Moffitt.

Risks

• Various closing conditions for the tender offer and merger, including the minimum tender condition and the 'Closing Net Cash' condition, may not be satisfied or waived.
• Uncertainties exist regarding the percentage of Turnstone's stockholders who will tender their shares in the Offer.
• There is a possibility that competing offers for Turnstone could be made.
• The merger and related transactions may not be completed in a timely manner, or at all, which could adversely affect Turnstone's business and the price of its common stock.
• Significant costs are associated with the proposed transactions.
• Stockholder litigation in connection with the transactions may arise, potentially resulting in significant costs of defense, indemnification, and liability.
• Activities related to the CVR agreement may not result in any value to the Company's stockholders, particularly if contingent proceeds are not received within one year following the merger closing.
• The 'Closing Net Cash' condition requires the company's net cash to be no less than $2,000,000, and failure to meet this could prevent the merger.
• The closing conditions for the Asset Purchase Agreement with Moffitt may not be met.

Future Outlook

The document indicates that Turnstone Biologics will be acquired by XOMA Royalty, leading to the winding down of Turnstone's operations and research and development activities. The future outlook for Turnstone as an independent entity is the cessation of its core business, with its assets and certain liabilities being transferred to XOMA and Moffitt. The CVR provides a potential future payment stream for former Turnstone stockholders based on specific contingent events related to tax receivables and a lease security deposit.

Management Comments

• The Company's Board of Directors has unanimously determined that the Offer, the Merger and the other transactions contemplated by the Merger Agreement and the CVR Agreement are fair to and in the best interest of the Company and its stockholders, approved and declared advisable the Merger and the execution, delivery and performance by the Company of the Merger Agreement and the consummation of the Transactions, resolved that the Merger Agreement and the Merger shall be governed by and effected under Section 251(h) of the Delaware General Corporation Law and that the Merger shall be consummated as soon as practicable following the Offer Closing Time, and recommended that the Company's stockholders accept the Offer and tender their shares of Common Stock pursuant to the Offer.

Industry Context

This acquisition represents a strategic shift for Turnstone, moving from an active biotechnology company focused on TIL therapy development to being acquired by a royalty aggregator, XOMA Royalty. This suggests a pivot away from direct drug development for Turnstone, potentially due to challenges in its clinical programs (as evidenced by the TIDAL-01 asset sale to Moffitt) or a strategic decision to monetize remaining assets. For XOMA Royalty, it's an expansion of its portfolio of milestone and royalty rights, aligning with its business model of acquiring future economics from therapeutic candidates. The sale of the TIDAL-01 program to Moffitt indicates a divestiture of a key R&D asset, which could be a sign of program discontinuation or a strategic realignment for Turnstone prior to the acquisition.

Comparison to Industry Standards

• The acquisition price of $0.34 per share plus a CVR is a relatively low valuation for a publicly traded biotechnology company, suggesting that Turnstone's pipeline or financial position may have been significantly distressed, leading to a 'wind-down' process.
• The cancellation of stock options for no consideration is unfavorable for option holders and is not a standard practice in all mergers, often indicating a low valuation or out-of-the-money options.
• The non-transferable nature of the CVRs is a common feature in such deals, but it limits liquidity for recipients compared to publicly traded CVRs.
• The assumption of a $20 million contingent milestone payment by Moffitt related to the Myst Merger Agreement is a significant liability transfer, which could be seen as a positive for Turnstone's balance sheet prior to the acquisition.
• The 'wind-down process' and termination of R&D activities are indicative of a company ceasing operations rather than being acquired for its ongoing business, which is a less common outcome for publicly traded biotech firms unless facing significant clinical or financial setbacks.

Management Changes

Corporate Governance

Legal Proceedings

• Potential stockholder litigation in connection with the transactions, which may result in significant costs of defense, indemnification, and liability.
• Existing stockholder litigation related to the Transactions, including demand letters seeking supplemental disclosures in the Schedule 14D-9 or books and records of the Company under Section 220 of the DGCL.

Related Party Transactions

• Separation and Consulting Agreements with Chief Executive Officer Sammy Farah and Chief Operating Officer Saryah Azmat, detailing severance and other payments upon their employment termination in connection with the Transactions.

Stakeholder Impact

• **Shareholders**: Will receive a low cash price of $0.34 per share plus a non-transferable CVR, which offers limited potential for additional value and lacks liquidity. Stock options are cancelled for no consideration, representing a significant loss for option holders.
• **Employees**: The company is undergoing a 'wind-down process' of operations and R&D activities, implying significant job losses for most employees, although the CEO and COO have separation agreements.
• **Customers/Partners**: The company's core business of developing TIL therapy is being wound down, and its TIDAL-01 program assets are being sold, indicating a cessation of product development and commercialization activities.
• **Creditors**: The 'Closing Net Cash' condition and the assumption of certain liabilities by Moffitt aim to manage the company's financial obligations, but the overall wind-down suggests a shift in the company's financial standing.

Next Steps

• XOMA Royalty to commence the tender offer by July 10, 2025.
• Turnstone to file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC.
• Merger Sub will merge with Turnstone following the completion of the tender offer.
• Turnstone's Chief Executive Officer and Chief Operating Officer's employment will terminate on July 31, 2025, and June 30, 2025, respectively, with consulting roles continuing until the merger closing.
• Turnstone will terminate or withdraw from participation in any 401(k) plans and other ERISA employee benefit plans prior to the merger closing.
• Turnstone will obtain and fully pay the premium for tail directors and officers liability insurance policies.
• Turnstone's securities will be de-listed from Nasdaq and de-registered under the Exchange Act as promptly as practicable following the Effective Time.

Key Dates

Recommendation

Keywords

Merger, Acquisition, Tender Offer, Contingent Value Right, CVR, Biotechnology, Oncology, TIL therapy, Asset Sale, SEC filing, 8-K, XOMA Royalty Corporation, Turnstone Biologics Corp., Corporate Governance, Financial Reporting, Risk Management, Strategic Analysis, Liquidation, Wind-Down